Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 197

recruiting
3 977
countries
28
conditions
2 105

3 664 trials match your criteria

Testicular germ cell cancer

Not recruiting

Study Comparing Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin versus High-Dose Chemotherapy with Paclitaxel and Drug Combination for Relapsed Germ Cell Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Carboplatin

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on Batoclimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab

Cutaneous lupus erythematosus

Not recruiting

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for Patients with Severe Pulmonary Arterial Hypertension at High Risk of Mortality

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept

Hormone-refractory prostate cancer

Not recruiting

Study of Cabozantinib and Atezolizumab Compared to Hormonal Therapy in Adults with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Neovascular age-related macular degeneration

Not recruiting

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Cystic fibrosis

Not recruiting

Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor in Children and Adults with Cystic Fibrosis Aged 2 Years and Older

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Elexacaftor

Idiopathic pulmonary fibrosis

Not recruiting

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Neuroendocrine tumour

Not recruiting

Study of Cabozantinib in Adults with Advanced Low-Grade Neuroendocrine Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.